📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Advanced Enzyme Technologies Assigned [ICRA]AA- (Stable) and [ICRA]A1+ Ratings for ₹100 Cr Limits
Advanced Enzyme Technologies Limited has received high-grade credit ratings from ICRA for its bank facilities totaling ₹100 crore. The long-term fund-based facilities of ₹40 crore were assigned an [ICRA]AA- rating with a Stable outlook, indicating a high degree of safety. Short-term non-fund based limits of ₹15 crore received the highest [ICRA]A1+ rating, reflecting very strong credit quality. Additionally, ₹45 crore in unallocated limits were assigned dual [ICRA]AA- and [ICRA]A1+ ratings.
Key Highlights
ICRA assigned [ICRA]AA- (Stable) rating for ₹40 crore long-term fund-based cash credit facilities.
Short-term non-fund based limits of ₹15 crore received the highest [ICRA]A1+ rating.
Unallocated limits of ₹45 crore were assigned dual ratings of [ICRA]AA- (Stable) and [ICRA]A1+.
The total bank instrument amount rated by ICRA stands at ₹100 crore.
Ratings reflect a high degree of safety regarding timely servicing of financial obligations and very low credit risk.
💼 Action for Investors
The assignment of high credit ratings confirms the company's strong financial profile and low default risk. Investors should view this as a positive indicator of the company's solvency and ability to manage its debt obligations effectively.
Advanced Enzyme Q3 FY26: PAT Rises 11% YoY to ₹432M; EBITDA Margins Contract to 29%
Advanced Enzyme Technologies reported a 2% YoY revenue growth to ₹1,719 million for Q3 FY26, though sequential revenue dropped 7%. While PAT increased 11% YoY to ₹432 million, EBITDA fell 11% YoY with margins contracting to 29% from 33% due to weakness in the Human Healthcare segment. Animal Healthcare and Bioprocessing segments provided support with 22% and 13% YoY growth, respectively. Management remains confident in full-year targets despite global trade disruptions and tariff shifts.
Key Highlights
Q3 FY26 Revenue reached ₹1,719 million, up 2% YoY but down 7% sequentially.
PAT for the quarter rose 11% YoY to ₹432 million with a 25% PAT margin.
EBITDA declined 11% YoY to ₹494 million, impacted by lower sales in Pharma and Nutrition.
Animal Healthcare segment grew 22% YoY to ₹241 million, contributing 14% of total revenue.
9M FY26 performance remains strong with revenue up 15% and PAT up 20% YoY.
💼 Action for Investors
Investors should monitor the stabilization of the Human Healthcare segment and the impact of US tariffs on export margins. The company's diversified portfolio and subsidiary turnarounds like Evoxx provide some cushion against core segment volatility.
Advanced Enzyme Reverses ₹159.64 Million Provision Following Favorable US Court Ruling
Advanced Enzyme Technologies' US-based subsidiary, AST, has received a favorable ruling from the US Court of Appeals in a lawsuit filed by World Nutrition Inc. As a result, the company has reversed a previously created provision of ₹159.64 million. This reversal has been accounted for in the financial results for the quarter ended December 31, 2025. This development is expected to positively impact the net profit for the reported quarter by removing a significant legal liability.
Key Highlights
Reversal of ₹159.64 million provision related to the AST lawsuit in the USA.
Favorable decision received from the United States Court of Appeals for the Ninth Circuit.
The financial impact is reflected in the un-audited results for the quarter ended December 31, 2025.
The lawsuit was originally filed by World Nutrition Inc. (WNI) against the step-down subsidiary AST.
The reversal was noted and approved by the Audit Committee and Board of Directors on January 31, 2026.
💼 Action for Investors
Investors should factor in this one-time gain in the Q3 FY26 earnings which will boost the bottom line. The resolution of this legal matter reduces uncertainty regarding the company's US operations.
Advanced Enzyme Q3 FY26: PAT Grows 11% YoY to ₹432 Mn; EBITDA Margins Contract to 29%
Advanced Enzyme Technologies reported a modest 2% YoY revenue growth in Q3 FY26, reaching ₹1,719 million, though revenue declined 7% sequentially. While PAT increased 11% YoY to ₹432 million, EBITDA faced pressure, declining 11% YoY with margins contracting from 33% to 29%. The growth was led by the Animal Nutrition (+22% YoY) and Industrial Bio-processing (+13% YoY) segments, which helped offset a 6% decline in the core Human Nutrition business. Geographically, strong growth in India and Rest of World was partially offset by an 11% decline in the Americas market.
Key Highlights
Consolidated Revenue grew 2% YoY to ₹1,719 million, but declined 7% on a QoQ basis.
EBITDA de-grew by 11% YoY to ₹494 million, with EBITDA margin standing at 29%.
PAT increased 11% YoY to ₹432 million, supported by an exceptional gain of ₹112 million.
Animal Nutrition segment showed strong momentum with 22% YoY growth to ₹241 million.
9M FY26 performance remains healthy with Revenue and PAT up 15% and 20% respectively compared to 9M FY25.
💼 Action for Investors
Investors should monitor the recovery in the high-margin Human Nutrition segment and the stabilization of margins in the Americas. While 9-month growth is strong, the quarterly EBITDA contraction suggests rising operational costs that need to be watched.
Advanced Enzymes Q3 PAT Up 11% YoY to ₹432 Mn; EBITDA Margins Contract to 29%
Advanced Enzyme Technologies reported a modest 2% YoY revenue growth in Q3 FY26 to ₹1,719 million, though revenue declined 7% sequentially. While PAT grew 11% YoY to ₹432 million, EBITDA margins saw a significant contraction to 29% from 33% in the previous year. The Human Nutrition segment, the company's largest, faced a 6% YoY decline due to weakness in Pharma/API markets, while Animal Nutrition and Bio-Processing showed strong growth of 22% and 13% respectively. For the nine-month period, the company maintains a healthy growth trajectory with PAT up 20% YoY.
Key Highlights
Q3 FY26 Revenue grew 2% YoY to ₹1,719 Mn, but fell 7% QoQ due to Pharma/API weakness.
PAT increased 11% YoY to ₹432 Mn, while 9M FY26 PAT stands at ₹1,284 Mn, up 20% YoY.
EBITDA margins compressed to 29% in Q3 FY26 compared to 33% in the same quarter last year.
Animal Nutrition segment delivered robust 22% YoY growth, reaching ₹241 Mn in Q3 FY26.
Domestic sales grew 6% YoY to ₹801 Mn, now accounting for 47% of total revenue.
💼 Action for Investors
Investors should monitor the recovery in the Human Nutrition segment and the stabilization of EBITDA margins in upcoming quarters. The company's zero-debt status and expansion into the B2C nutraceutical space via the Wellfa brand provide long-term growth visibility.
Advanced Enzyme Q3 Net Profit Rises 11% YoY to ₹431.8M; To Invest in 26% Wind Power SPV
Advanced Enzyme Technologies reported a steady performance for Q3 FY26, with revenue from operations growing 9.1% YoY to ₹1,845.28 million. Net profit for the quarter increased by 11% YoY to ₹431.83 million, although it saw a slight sequential dip from ₹447.33 million in Q2. Strategically, the company has pivoted its renewable energy strategy, opting to acquire up to a 26% stake in a Group Captive Wind Power SPV while cancelling a previously planned solar project. This move is aimed at securing long-term energy cost efficiencies for its manufacturing operations.
Key Highlights
Revenue from operations increased 9.1% YoY to ₹1,845.28 million in Q3 FY26.
Net profit for the quarter stood at ₹431.83 million, up from ₹388.76 million in the year-ago period.
Nine-month FY26 revenue reached ₹5,423.90 million with a net profit of ₹1,283.56 million.
Board approved an investment of up to 26% equity stake in a Special Purpose Vehicle (SPV) for a Group Captive Wind Power Plant.
The company officially withdrew from a previously proposed group captive solar power project in favor of the wind power initiative.
💼 Action for Investors
Investors should take note of the consistent YoY growth and the strategic shift toward wind energy which could improve operational margins over time. The stock remains a watch for steady earnings performance and successful execution of the captive power project.
Advanced Enzyme Q3 FY26 Net Profit Rises 11% YoY to ₹43.2 Cr; Wind Power Project Approved
Advanced Enzyme Technologies reported a steady performance for Q3 FY26, with consolidated revenue growing 7.3% YoY to ₹184.5 crore. Net profit for the quarter increased by 11.1% YoY to ₹43.2 crore, although it saw a slight sequential dip from the previous quarter. The company also announced a strategic shift in its renewable energy plans, opting for a 26% stake in a Group Captive Wind Power Plant instead of a previously planned solar project. For the nine-month period ended December 2025, the company showed robust growth with net profit rising nearly 20% to ₹128.4 crore.
Key Highlights
Consolidated Revenue from operations grew 7.3% YoY to ₹1,845.3 million in Q3 FY26.
Net Profit for the quarter stood at ₹431.8 million, an 11.1% increase compared to ₹388.8 million in Q3 FY25.
Nine-month (9M FY26) Net Profit reached ₹1,283.6 million, up 19.7% from ₹1,072.5 million in the previous year.
Board approved a 26% equity investment in a Group Captive Wind Power SPV, replacing a prior solar project to optimize energy costs.
Earnings Per Share (EPS) for the quarter improved to ₹3.80 from ₹3.37 in the corresponding quarter last year.
💼 Action for Investors
The company continues to demonstrate consistent year-on-year growth and is actively managing operational costs through renewable energy shifts. Investors should maintain a positive outlook while monitoring the integration of the new Nutrazyme subsidiary and the execution of the wind power project.